AAP
CRVS icon

Arax Advisory Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Arax Advisory Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$77 – 3910
2025
Q4 		$77 Sell
10
-136
-93% -$1.07K ﹤0.01% 3866
2025
Q3 		$1.08K Buy
+146
New +$747 ﹤0.01% 3242

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Arax Advisory Partners's CRVS Position: Q1 2026 in Review

Arax Advisory Partners sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 10 shares — an estimated $77 sold.

Arax Advisory Partners first reported a position in CRVS in Q3 2025 and held it in 2 quarters. The position peaked at $1.08K in Q3 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Arax Advisory Partners reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 10 Corvus Pharmaceuticals shares in Q1 2026, an estimated $77.
  • Arax Advisory Partners first reported a position in Corvus Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's Corvus Pharmaceuticals position peaked at $1.08K in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.